Heron Therapeutics (NASDAQ: HRTX) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.01) by Infinity percent. This is a 50 percent decrease over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $37.666 million which missed the analyst consensus estimate of $42.200 million by 10.74 percent. This is a 1.25 percent increase over sales of $37.200 million the same period last year.